Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder

Schizophrenia Research
Matcheri S KeshavanNina Schooler

Abstract

Few treatment studies of schizotypal personality disorder (SPD) have investigated the new, atypical antipsychotic drugs. This study examined the efficacy and tolerability of olanzapine, an atypical antipsychotic drug, in a series of patients with DSM-IV diagnosed schizotypal personality disorder. This was a 26-week, open-label study with flexible dose design in 11 subjects with a diagnosis of schizotypal personality disorder based on Structured Clinical Interview for DSM-IV (SCID) and Personality Disorder Examination (PDE Journal of Psychiatric Disorders 1 (1987) 1). Subjects were treated with a low dose (average 9.32 mg/day) of olanzapine. Psychopathology was assessed at baseline and at the end of the study and analyzed with last observation carried forward analysis. Patients showed significant improvements in psychosis and depression ratings, as well as in overall functioning. Olanzapine was well tolerated, though significant weight gain was observed. This study provides preliminary data regarding olanzapine efficacy and tolerability in schizotypal personality disorder subjects. These data need to be confirmed in larger controlled clinical trials.

References

Aug 1, 1992·The British Journal of Psychiatry : the Journal of Mental Science·G Stein
Jan 1, 1989·Acta Psychiatrica Scandinavica·H V Jensen, J Andersen
Aug 1, 1989·Journal of Clinical Psychopharmacology·P H SoloffJ M Perel
Nov 1, 1993·Comprehensive Psychiatry·F R Frankenburg, M C Zanarini
Aug 29, 1997·Schizophrenia Research·S Park, K McTigue
May 3, 2002·The American Journal of Psychiatry·Kristin S CadenheadDavid L Braff

❮ Previous
Next ❯

Citations

Jan 1, 2008·Primary Care Companion to the Journal of Clinical Psychiatry·Ajay KumarSuresh Bada Math
Feb 19, 2005·Current Psychiatry Reports·Katherine Seeber, Kristin S Cadenhead
Aug 25, 2007·Annual Review of Clinical Psychology·Adrian Raine
Aug 30, 2012·Journal of Personality Disorders·Eran ChemerinskiLarry J Siever
Oct 27, 2007·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Sabine C HerpertzUNKNOWN World Federation of Societies of Biological Psychiatry (WFSBP)
Aug 19, 2008·International Journal of Stroke : Official Journal of the International Stroke Society·Maaike DirksUNKNOWN Promoting Acute Thrombolysis for Ischaemic Stroke (PRACTISE)
Jun 21, 2006·Expert Review of Neurotherapeutics·Kimberly H LittrellNicole M Wolf
Mar 30, 2017·Journal of Psychopharmacology·Klaus Damgaard JakobsenJimmi Nielsen
Dec 2, 2005·Journal of Psychiatric Practice·Michael H AllenUNKNOWN Expert Consensus Panel for Behavioral Emergencies 2005
Mar 8, 2016·The Mental Health Clinician·Jessa KochChristopher Thomas
Oct 5, 2018·NPJ Schizophrenia·Sophie K KirchnerAlkomiet Hasan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.